Literature DB >> 33574408

The association between impairment of HDL cholesterol efflux capacity and atrial remodeling in atrial fibrillation.

Asuka Minami-Takano1,2, Hiroshi Iwata3, Katsutoshi Miyosawa1,4, Tomoyuki Shiozawa1, Hidemori Hayashi1, Takehiro Funamizu1, Kai Ishii1, Yui Nozaki1, Haruna Tabuchi1, Gaku Sekita1, Kazunori Shimada1, Masataka Sumiyoshi5, Yuji Nakazato6, Hiroyuki Daida1, Tohru Minamino1,7.   

Abstract

This cross-sectional study enrolled 202 patients with atrial fibrillation (AF) who had undergone catheter ablation and evaluated the association between high-density lipoprotein (HDL) functionality, cholesterol efflux capacity (CEC) of HDL, and the pathophysiology of left atrial structural remodeling. Participants were divided into two groups, based on their left atrial volume index (LAVI) (< 34 mL/m2, n = 60 vs. LAVI ≥ 34 mL/m2, n = 142). We quantified three types of HDL CECs by the presence or absence of cyclic-AMP, as entire, and CEC dependent or not dependent on ATP binding cassette transporter A1 (ABCA1) and termed them Global CEC, ABCA1 CEC, and Non-ABCA1 CEC, respectively. Consequently, Global and Non-ABCA1 CECs were significantly impaired in patients with an enlarged LA (Global CEC: p = 0.039, Non-ABCA1 CEC: p = 0.022). Logistic regression analyses demonstrated that Non-ABCA1 CEC was significantly associated with an enlarged LA after adjusting for the conventional risk factors of AF. Furthermore, the association of higher Non-ABCA1 CEC with an enlarged LA was independent of serum levels of HDL cholesterol and serum myeloperoxidase (Odds ratio of 1 standard deviation higher: 0.64, 95% confidence interval: 0.43-0.95, p = 0.027). The findings of this study indicate the potential contribution of reduced Non-ABCA1 CEC in HDL to the pathophysiology in left atrial structural remodeling of patients with AF.

Entities:  

Year:  2021        PMID: 33574408     DOI: 10.1038/s41598-021-82998-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  35 in total

1.  Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.

Authors:  M Guerin; T S Lassel; W Le Goff; M Farnier; M J Chapman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-01       Impact factor: 8.311

Review 2.  Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy.

Authors:  William H Maisel; Lynne Warner Stevenson
Journal:  Am J Cardiol       Date:  2003-03-20       Impact factor: 2.778

Review 3.  Inflammation and the pathogenesis of atrial fibrillation.

Authors:  Yu-Feng Hu; Yi-Jen Chen; Yenn-Jiang Lin; Shih-Ann Chen
Journal:  Nat Rev Cardiol       Date:  2015-01-27       Impact factor: 32.419

4.  HDL cholesterol efflux capacity and incident cardiovascular events.

Authors:  Anand Rohatgi; Amit Khera; Jarett D Berry; Edward G Givens; Colby R Ayers; Kyle E Wedin; Ian J Neeland; Ivan S Yuhanna; Daniel R Rader; James A de Lemos; Philip W Shaul
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

5.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.

Authors:  E J Benjamin; P A Wolf; R B D'Agostino; H Silbershatz; W B Kannel; D Levy
Journal:  Circulation       Date:  1998-09-08       Impact factor: 29.690

6.  The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages.

Authors:  Margarita de la Llera-Moya; Denise Drazul-Schrader; Bela F Asztalos; Marina Cuchel; Daniel J Rader; George H Rothblat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-01-14       Impact factor: 8.311

7.  Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.

Authors:  Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray
Journal:  Circulation       Date:  2013-12-17       Impact factor: 29.690

8.  Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols.

Authors:  P W Wilson; R J Garrison; W P Castelli; M Feinleib; P M McNamara; W B Kannel
Journal:  Am J Cardiol       Date:  1980-10       Impact factor: 2.778

Review 9.  Trials and Tribulations of CETP Inhibitors.

Authors:  Alan R Tall; Daniel J Rader
Journal:  Circ Res       Date:  2017-10-10       Impact factor: 17.367

10.  Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies.

Authors:  Christian M Madsen; Anette Varbo; Børge G Nordestgaard
Journal:  Eur Heart J       Date:  2017-08-21       Impact factor: 29.983

View more
  1 in total

1.  High-Density Lipoprotein Changes in Alzheimer's Disease Are APOE Genotype-Specific.

Authors:  Brian V Hong; Jingyuan Zheng; Joanne K Agus; Xinyu Tang; Carlito B Lebrilla; Lee-Way Jin; Izumi Maezawa; Kelsey Erickson; Danielle J Harvey; Charles S DeCarli; Dan M Mungas; John M Olichney; Sarah T Farias; Angela M Zivkovic
Journal:  Biomedicines       Date:  2022-06-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.